| Prev Close | 0.65 |
| Open | 0.67 |
| Day Low/High | 0.67 / 0.72 |
| 52 Wk Low/High | 0.49 / 1.40 |
| Volume | 135.33K |
| Avg Volume | 534.20K |
| Exchange | NASDAQ |
| Shares Outstanding | 26.54M |
| Market Cap | 18.58M |
| EPS | -0.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
OXiGENE Announces Positive Initial Data From Phase 1b Study Of CA4P In Combination With Pazopanib In Patients With Advanced Recurrent Ovarian Cancer
-- Based on Positive Safety Data and Preliminary Signs of Efficacy, Study Expected to Advance to Phase 2 Portion in Early 2016 --
OXiGENE Appoints Matthew M. Loar As Chief Financial Officer
Adds Broad Finance and Operating Experience to Company's New Leadership
OXiGENE (OXGN) Stock Gains on Positive FDA Feedback for Cancer Treatment Trials
OXiGENE (OXGN) shares are rising after the company announced that the FDA gave preliminary approval for the method of its phase 3 cancer treatment study.
OXiGENE Appoints Bill Schwieterman, M.D., As President And Chief Executive Officer
Dai Chaplin Becomes Chief Scientific Officer
OXiGENE Reports First Quarter 2015 Financial Results
Strengthened Cash Position; Fosbretabulin and OXi4503 Clinical Programs Advancing